等待開盤 11-19 09:30:00 美东时间
+0.120
+2.84%
Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(1.23) per share which beat the analyst consensus estimate of $(1.31) by 6.11 percent. This is a 64.35 percent increase over losses of $(3.45) per share
11-12 20:02
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), is a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections. It announced today
10-28 20:19
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule
10-09 19:35
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock moved upwards by 137.1% to $10...
10-09 01:06
Shares of Confluent Inc (NASDAQ:CFLT) rose sharply in pre-market trading. Confl...
10-08 16:43
今日重点评级关注:Maxim Group:上调Adial Pharmaceuticals评级至"买入",目标价1.5美元;BTIG:维持Climb Bio"买入"评级,目标价从7美元升至8美元
10-01 20:13
The Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on Acurx's Pediatric Investigation Plan (PIP) for ibezapolstat use in children with C. difficile infectionReceipt of this
09-30 19:34
Acurx Pharmaceuticals ( ($ACXP) ) just unveiled an update. On September 16, 202...
09-23 04:57
An announcement from Acurx Pharmaceuticals ( ($ACXP) ) is now available. On Sep...
09-20 05:47